ACE2 is the critical *in vivo* receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFN γ -driven immunopathology

Authors:

Riem Gawish^{1,*}, Philipp Starkl^{1,*}, Lisabeth Pimenov¹, Anastasiya Hladik¹, Karin Lakovits¹, Felicitas Oberndorfer², Shane J.F. Cronin³, Anna Ohradanova-Repic⁴, Gerald Wirnsberger⁵, Benedikt Agerer⁶, Lukas Endler⁶, Tümay Capraz⁷, Jan W. Perthold⁷, Astrid Hagelkruys³, Nuria Montserrat⁸, Ali Mirazimi⁹, Louis Boon¹⁰, Hannes Stockinger⁴, Andreas Bergthaler⁶, Chris Oostenbrink⁷, Josef M. Penninger^{3,11}, and Sylvia Knapp¹

¹ Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria, ² Department of Pathology, Medical University of Vienna, Vienna, Austria, ³ Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria, ⁴ Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; ⁵ Aperiion Biologics, Vienna, Austria, ⁶ CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria, ⁷ Institute of Molecular Modeling and Simulation, Department of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Vienna, Austria, ⁸ Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Technology (BIST), Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain, ⁹ Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden; National Veterinary Institute, Uppsala, Sweden, ¹⁰ Polpharma Biologics, Utrecht, The Netherlands, ¹¹ Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada

* Contributed equally

Short title:

Immunity and critical role of ACE2 in murine COVID-19

Corresponding Author:

Sylvia Knapp, MD, PhD,

Laboratory of Infection Biology, Dept. of Medicine I, Medical University of Vienna

Waehringer Guertel 18-20, 1090 Vienna, Austria

Phone: +43-1-40400-51390, Fax: +43-1-40400-51670

E-mail: sylvia.knapp@meduniwien.ac.at

Key points:

- The mouse-adapted SARS-CoV-2 strain *maVie16* causes fatal disease in BALB/c mice and substantial inflammation, pneumonia and immunity in C57BL/6 mice
- TNF α /IFN γ blockade ameliorates *maVie16*-induced immunopathology
- *MaVie16* infection depends on ACE2 and soluble ACE2 inhalation can prevent disease

Summary

Despite tremendous progress in the understanding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited. We generated *maVie16*, a mouse-adapted SARS-CoV-2, by serial passaging of a human isolate. *In silico* modelling revealed how Spike mutations of *maVie16* enhanced interaction with murine ACE2. *MaVie16* induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (*mCOVID-19*) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFN γ and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented *mCOVID-19* development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from *mCOVID-19*, revealing a novel and efficient treatment. Thus, we here present *maVie16* as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 *in vivo*.

Keywords

mouse-adapted SARS-CoV-2; *maVie16*; COVID-19 mouse model; C57BL/6; BALB/c; cytokine storm; IFN; TNF; ACE2 targeting; COVID-19 therapy

Introduction

SARS-CoV-2, was identified as the causative agent of COVID-19 in December 2019 and has since (until August 5th, 2021) infected 200 million people and caused 4.3 million confirmed deaths worldwide (WHO, 2021b). Upon adaptation to humans, SARS-CoV-2 evolution gave rise to multiple variants including novel SARS-CoV-2 variants of concern (VOCs), characterized by increased transmissibility and/or virulence, or reduced effectiveness of countermeasures such as vaccinations or antibody therapies (WHO, 2021a). Clinical symptoms upon SARS-CoV-2 infection show a wide range, from asymptomatic disease to critical illness (Chen *et al.*, 2020; Paranjpe *et al.*, 2020). Severe COVID-19 is characterized by progressive respiratory failure, often necessitating hospitalization and mechanical ventilation. Fatal disease is linked to acute respiratory distress syndrome (ARDS), associated with activation of inflammation and thrombosis, often resulting in multi-organ failure (Chen *et al.*, 2020; Paranjpe *et al.*, 2020). Epidemiologically, several risk factors, such as age, male sex, diabetes and obesity have been found to be associated with the development of severe COVID-19 (Richardson *et al.*, 2020; Zhou *et al.*, 2020). However, early immunologic determinants driving disease severity and outcome of SARS-CoV-2 infection remain elusive.

While SARS-CoV-2 replicates primarily in nasopharyngeal and type-II alveolar epithelial cells in the lower respiratory tract, recent data point towards a broader cellular tropism under certain conditions (Sunngak *et al.*, 2020; Ziegler *et al.*, 2020). This largely correlates with angiotensin converting enzyme-2 (ACE2) expression, the entry receptor for SARS-CoV-2 (Hoffmann *et al.*, 2020), and TMPRSS2 expression, a protease, which supports viral cell entry (Hoffmann *et al.*, 2020; Liu *et al.*, 2021; Murgolo *et al.*, 2021). Severe disease seems to be driven by a circuit of T cells and macrophages causing a cytokine release syndrome, immunothrombosis and resulting tissue damage that resembles macrophage activation syndrome (Mangalmurti and Hunter, 2020). As such, IFN γ released by T cells drives the emergence of pathologically activated, hyperinflammatory monocytes and macrophages that produce large amounts of interleukin (IL)-6, TNF α and IL-1 β (Grant *et al.*, 2021). Although numerous studies investigated immune responses upon SARS-CoV-2 infection in humans, these studies are largely correlations in hospitalized patients with moderate to severe disease (Merad *et al.*, 2021).

Mechanistic data on early immunologic events driving COVID-19 remain sparse due to limited access to human samples and the scarcity of robust small animal models. Notably, mice are resistant to SARS-CoV-2 infection due to phylogenetic differences in ACE2 (Damas *et al.*, 2020;

Parolin et al., 2021). To circumvent the missing sensitivity of conventional mice, some groups studying SARS-CoV-2-related immune mechanisms take advantage of K18-hACE2 transgenic mice, which express human ACE2 under the epithelial cytokeratin-18 (K18) promoter (Winkler et al., 2020). However, K18-hACE2 mice are overly susceptible as they develop deadly SARS-CoV-2 encephalitis (in addition to pneumonia) in response to low infection doses, due to non-physiological and broad (over)expression of hACE2 (Kumari et al., 2021). Recently, four mouse-adapted SARS-CoV-2 strains have been generated by either genetic engineering (Dinnon et al., 2020) and/or serial passaging (Gu et al., 2020; Huang et al., 2021; Leist et al., 2020). However, while infectivity is achieved with all of these strains, only two (Huang et al., 2021; Leist et al., 2020) cause a pathology that mimics human disease, and pathological mechanisms are still poorly understood. Of note, the VOCs Beta/B.1.351 (Tegally et al., 2020) and Gamma/P1 (Voloch et al., 2020) have been recently found to productively replicate in mice without causing pneumonia (Montagutelli et al., 2021), indicating that additional mutations might further increase mouse infectivity and pathogenicity.

In this study, we report the generation of a novel mouse adapted SARS-CoV-2 virus, *maVie16*, which causes a disease reminiscent of COVID-19 in humans in two distinct wild type mouse strains, BALB/c and C57BL/6 mice. We find that the inflammatory cytokines TNF and IFN γ are important drivers of *maVie16* pathogenicity. Moreover, we provide the first genetic *in vivo* proof that ACE2 is the critical SARS-CoV-2 receptor. Finally, therapeutic inhalation of soluble ACE2 completely prevented disease. Our novel mouse *maVie16* infection model is thus a useful and relevant model to study immunology and determinants of SARS-CoV-2 infections and COVID-19 *in vivo*.

Results

Generation of the mouse-adapted SARS-CoV-2 strain *maVie16*

To generate a virus pathogenic to mice, we infected BALB/c mice with a human SARS-CoV-2 isolate (BetaCoV/Munich/BavPat1/2020; from here on referred to as *BavPat1* (Rothe *et al.*, 2020)), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days (Figure 1A). Infectivity was quickly established after the first few passages, as indicated by increasing SARS-CoV-2 genome copies detected in the lungs of infected mice (Figure 1B). While the viral load did not further change after passage 3, a progressive loss of body weight of mice infected with later stage passaged SARS-CoV-2 indicated enhanced pathogenicity of the virus (Figure 1C). Mice infected with passage 15 furthermore exhibited a severe drop in body temperature (Figure 1D). The transcriptional analysis of pulmonary inflammatory genes (including *il1b*, *ifng*, *il6* and *tnf*) 3 days after infection with the different passages revealed a progressively increasing inflammatory response (Figure 1E). These results indicate that our serial passaging protocol has allowed us to generate a highly infectious and pathogenic mouse-adapted SARS-CoV-2 variant (isolated from lungs of mice infected with passage 15) which we refer to as *maVie16* (mouse-adapted SARS-CoV-2 virus **Vienna**, passage **16**).

Genetic evolution of the *maVie16* Spike protein

To elucidate the mechanisms of mouse adaptation of *maVie16*, we sequenced SARS-CoV-2 genomes at all passages and compared the viral sequences to the original *BavPat1* isolate. Despite the substantially increased virulence in mice, we found only a limited number of mutations with high (> 0.5) allele frequencies, located in the Spike protein, open reading frame (ORF)1AB, and envelope (Figure 2A). Given the importance of Spike for SARS-CoV-2 infectivity, we were particularly interested in the three *de novo* mutations within its receptor binding domain (RBD) (Figure 2B). Most prominently, we observed the immediate appearance of Q498H after passage 1 (Figure 2B), which correlated with the early increase in viral load (and hence viral propagation) in infected mice (Figure 1B). After passage 12, we detected a glutamine to arginine exchange at position Q493R (Figure 2B). As of today, Q498H or Q493R have been observed in a few patient samples (16 and 196, respectively, according to the GSAID database (Shu and McCauley, 2017)) whereas the simultaneous appearance of both mutations was never reported in human isolates. Q498H and Q493R appear to have emerged sporadically and have not yet been reported in specific human SARS-CoV-2 strains. However, both mutations were reported in other mouse-adapted virus strains (Dinnon *et al.*, 2020; Gu *et al.*, 2020; Huang *et al.*, 2021), supporting their

critical role in the increased mouse specificity. In contrast to these apparently mouse-specific Spike RBD mutations, the K417 mutation (which appeared around passage 10; Figure 2B) has also been reported in two human SARS-CoV-2 variants of concern, i.e. Beta/B.1.351 (K417N) (Tegally *et al.*, 2020) and Gamma/P1 (K417T) (Voloch *et al.*, 2020).

Structural analyses of mouse and human ACE2 (mACE2 and hACE2, respectively) have shown that the surface of mACE2 consists of more negative charged amino acids than that of hACE2 (Figure S1A) (Rodrigues *et al.*, 2020). Indeed, the exchange of two glutamines (Q493 and Q498) to arginine and histidine, respectively, in the *maVie16* Spike results in a positive charged surface (Figure 2C). Detailed structural modeling of the *BavPat1* versus the *maVie16* Spike protein interface with mACE2 revealed that the *maVie16* Spike Q498H mutation would strengthen its interaction with mACE2 at amino acid D38, otherwise forming an intramolecular salt bridge with mACE2 H353 (Figure 2D). Similarly, the newly-introduced arginine at *maVie16* spike position 493 is predicated to efficiently interact with the negatively-charged mACE2 amino acid E35, thus further stabilizing the *maVie16* Spike/mACE2 interaction by neutralizing the otherwise unpaired negative charge of mACE2 glutamic acid (Figure 2D). Finally, the threonine at Spike position 417 (T417) of *maVie16*'s is predicted to enhance the interaction with the neutrally-charged asparagine at position 30 of mACE2 while the aspartic acid at this position in hACE2 forms a salt-bridge with lysine K417 of the original *BavPat1* isolate. Of note, *maVie16* showed similar propagation kinetics in Vero and Caco-2 cells as compared to *BavPat1* (Figure S1B). Thus, while the interaction with mACE2 is enhanced, the infectivity of human cells remained unchanged for *maVie16* and both simian and human cells continue to serve as a useful tool for *maVie16* propagation and titer determination. Taken together, our data indicate that only three distinct spike RBD mutations introduced during passaging could substantially enhance interaction with mACE2, without obvious effects on the interaction with hACE2.

MaVie16 causes severe pneumonia in BALB/c and C57BL/6 mice

We next performed dose response experiments of *maVie16* infections in BALB/c (B/c) and, as a commonly used mouse strain for genetic engineering, C57BL/6 (B/6) mice and monitored weight and body temperatures over 7 days. In BALB/c mice, *maVie16* was highly pathogenic and caused profound weight loss, starting around day 3 post infection (p.i.) at a dose of 4×10^3 TCID₅₀ (Figure 3A), whereas all tested higher doses caused an earlier weight loss (day 2 p.i.) and lethality starting at day 4 p.i. (Figure 3B). Notably, the loss of body weight correlated with hypothermia (Figure 3C).

In contrast to BALB/c mice, *maVie16* infection did not cause lethality nor significant hypothermia in C57BL/6 animals, albeit 1×10^5 (and higher) TCID₅₀ induced a profound but transient body weight loss of about 15-20% (Figure 3D to F). Interestingly, both mouse strains infected with 1×10^5 TCID₅₀ showed similar body weight loss (approximately 15%) at day 3 p.i., but while disease severity further increased in BALB/c animals, C57BL/6 mice recovered. In line with these data, BALB/c animals showed more severe lung pathologies compared to C57BL/6 mice, as revealed by histologic analyses of lungs on day 3 (Figure 3G and H). While the cumulative histological score revealed no differences between the strains, diffuse alveolar damage, characterized by alveolar collapse and septal thickening, was more pronounced in BALB/c mice (Figure 3I).

To compare our data with a widely used mouse model of COVID-19, we infected *K18-hACE2* transgenic mice (which express human ACE2 under control of the human keratin 18 promoter (McCray *et al.*, 2007; Oladunni *et al.*, 2020) with either 1×10^3 or 1×10^4 TCID₅₀ of *BavPat1* and monitored the disease course over 7 days. As expected (Oladunni *et al.*, 2020), *K18-hACE2* mice were most sensitive to infection and succumbed to *BavPat1* infections (Figure S2A and S2B). However, the disease course was profoundly different to that of *maVie16*-infected wild type animals. *BavPat1*-infected *K18-hACE2* mice appeared healthy until day 4 p.i. and then progressively lost weight until day 7, accompanied by hypothermia and death (Figure S2C-F). Death in *K18-hACE2* mice most likely results from severe encephalitis due to expression of hACE2 in neurons where ACE2 is normally not expressed (Hikmet *et al.*, 2020). These results show that *maVie16* causes severe pathology in BALB/c and profound, but transient, disease in C57BL/6 mice, recapitulating critical aspects (such as transient pneumonia and viral clearance) of human COVID-19.

Murine anti-SARS-CoV-2 immune responses

To better understand the pathophysiology of *mCOVID-19*, we next profiled immune cell dynamics in blood and lungs of C57BL/6 mice during acute infection and upon recovery. *MaVie16* (5×10^5 TCID₅₀) infection caused severe blood leukopenia on day 2 p.i. with a prominent reduction of lymphocytes, monocytes, neutrophils and NK cells (Figure 4A, Figure S3 and S4A). At the same time, we observed an expansion of peripheral plasmacytoid dendritic cells (pDCs) (Figure 4B), which are important antiviral effector cells capable of efficient and rapid type I interferon (IFN) production (Swiecki and Colonna, 2015).

Infection led to substantial pulmonary infiltration with leukocytes (Figure 4C), paralleling the development of pneumonia. A closer look at the inflammatory cell composition in the lungs revealed a remarkable infiltration with pDCs on day 2 p.i. (Figure 4C). Conventional dendritic cells (cDCs) transiently accumulated in the lung on day 5 p.i., followed by T helper and cytotoxic T cell infiltration and recruitment of monocytes on day 7 (Figure 4C and S4B). The abundance of other analyzed immune cell populations did not change substantially, and lung neutrophil numbers dropped around day 2 p.i. to return to baseline levels over the remaining disease course (Figure S4B). Surprisingly, pulmonary NK cells, which fulfill important antiviral functions (Bjorkstrom *et al.*, 2021), did not significantly expand in the lungs of *maVie16* infected C57BL6 mice (Figure S4B). In line with an early lung pDC accumulation, we found rapid induction of type I IFN-inducible genes, such as *elf2ak2* (protein kinase R/PKR) and *ifit1*, accompanied by a profound *il6* response; the expression of *tnf*, *il10*, *il1b* and *tgfb* peaked between day 5 and 7 p.i. (Figure 4D and S4C). The *ifng* induction reached a maximum on day 7, coinciding with the increased numbers of T cells which are prominent sources of IFN γ (Figure 4D).

In C57BL/6 mice infected with *maVie16* (5×10^5 TCID $_{50}$), lung weights significantly increased by day 5 to 7 p.i. (Figure 5A). Lung viral titers peaked at day 2 p.i. and then gradually declined (Figure 5B). Immunohistochemical staining for SARS-CoV-2 nucleoprotein on lung slides confirmed the initial presence and subsequent elimination of viral particles (Figure 5C). Histological analyses of lung tissue revealed progressive interstitial and perivascular infiltration and signs of diffuse alveolar damage, such as alveolar collapse and septal thickening, peaking from day 5 to 7, and resolving by day 14 p.i. (Figure 5C). Interestingly, vasculitis was observed early after infection (day 2) and resolved at later timepoints (Figure 5C and 5D). Moreover, most acute inflammatory parameters (including cytokine genes, innate immune cells and lung tissue weights) had returned close to baseline at day 14 p.i. (Figures 4, 5A-D and S4), confirming resolution of inflammation. Onset of adaptive immunity, as indicated by expansion of pulmonary cDCs and T helper cells by day 5 and 7 (Figure 4C), as well as by increased spleen weight on day 7 p.i. (Figure S4D) was followed by an efficient humoral immune response, reflected by significantly increased levels of anti-SARS-CoV-2 Spike protein-specific plasma IgG1, IgG2b and IgA antibodies on day 14 p.i. (Figure 5E). These data show that *maVie16* infection causes severe, yet transient, lung inflammation in C57BL/6 mice. Furthermore, *maVie16* induces a rapid type I IFN response, which correlated with a marked expansion of pDCs.

Distinct differences in anti-viral immunity of BALB/c vs. C57BL/6 mice

In an attempt to elucidate underlying mechanisms for the different susceptibility of BALB/c and C57BL/6 mice, we infected both mouse strains side by side with 1×10^5 TCID₅₀ of *maVie16* and monitored their respective immune responses 3 days later (as BALB/c and C57BL/6 mice showed comparable weight loss and no mortality at this dose and time point; Figure 3). Both mouse strains exhibited a decline in blood leukocytes, including lymphocytes and NK cells, upon infections with *maVie16* (Figure 6A and S5A). Also, pulmonary immune cell dynamics did not differ between the strains, except for an expansion of NK cells in BALB/c mice, and elevated pDC numbers in C57BL/6 animals (Figure 6B and S5B). Higher NK cell abundance correlated with increased pulmonary IFN γ levels in BALB/c mice, whereas *I1b* was slightly higher in C57BL/6 animals 3 days after infection (Figure 6C and S5C). Plasma cytokine levels (Figure S5D), viral loads (Figures S5E) as well as spleen and lung weight (Figure S5F) were comparable between the two mouse strains. These data identify differences in the early local inflammatory response between *maVie16*-infected BALB/c as compared to C57BL/6 animals.

A pathogenic role of IFN γ and TNF in disease severity

Several reports illustrated a correlation between systemic cytokine responses, lung injury and prognosis in humans suffering from severe COVID-19. A particularly detrimental role was attributed to excessive IFN γ levels (Grant *et al.*, 2021). Moreover, an earlier study showed that the combined activity of IFN γ and TNF caused inflammatory types of cell death, which was named PANoptosis, i.e. pyroptosis, apoptosis and necroptosis, and that blocking these cytokines improved disease outcomes in *K18-hACE2* mice infected with human SARS-CoV-2 (Karki *et al.*, 2021). In accordance with these reports and our finding of higher IFN γ levels in highly susceptible BALB/c mice, we tested if blocking IFN γ and TNF might reduce disease severity after *maVie16* infection. *MaVie16*-infected (1×10^5 TCID₅₀) BALB/c mice treated intraperitoneally with a mixture of anti-IFN γ and anti-TNF antibodies (on days 1 and 3 p.i.; Figure 6D and S6A) significantly improved weight loss (Figure 6E) and decreased lung weights (Figure 6G), the viral load (Figure S6B) as well as circulating monocyte levels (Figure S6C) while it had only minor effects on body temperature (Figure 6F). In C57BL/6 mice, the same treatment had no effects on body or lung weights, or viral load (Figure S6D, E, G and H), but significantly improved the altered body temperature and circulating leukocyte numbers (Figure S6F and I). Though other cytokines and chemokines must be involved, these results underline the therapeutic potential of IFN γ and TNF blockade as COVID-19 treatment.

ACE2 expression is essential for *maVie16* infections

We have previously shown using *Ace2* mutant mice that ACE2 is essential for *in vivo* SARS infections (Kuba *et al.*, 2005). ACE2 is also an important receptor for SARS-CoV-2, however other receptors have been critically proposed to mediate infections such as neuropilin-1 (Cantuti-Castelvetri *et al.*, 2020; Daly *et al.*, 2020) or CD147 (Wang *et al.*, 2020). Having developed the *maVie16* infection system, we could therefore ask one of the key questions to understand COVID-19: is ACE2 also the essential entry receptor for SARS-CoV-2 infections in a true *in vivo* infection model? To answer this question, we infected ACE2-deficient male *Ace2*^{-/-} mice (Figure 7A and S7A). In contrast to infected littermate control animals, *Ace2*^{-/-} mice were fully protected against (5×10^5 TCID₅₀) *maVie16*-induced pathology and showed stable body weight (Figure 7B) and temperature (Figure 7C). By day 3 p.i., ACE2 deficiency protected from pneumonia development as indicated by lower lung weight (Figure 7D) and the absence of any lung pathology (Figure 7E). Viral genome copy numbers at this time point were similar (Figure S7B). However, while infected cells were evenly distributed in wild type control lungs, we did not find any SARS-CoV-2 nucleocapsid-positive cells in lungs of *Ace2*^{-/-} animals (Figure 7F). These data support a gatekeeper role for ACE2 in mediating productive infection of lung epithelial cells with SARS-CoV-2. Thus, genetic inactivation of ACE2 protects mice from productive SARS-CoV-2 infections and lung pathologies.

Inhalation of ACE2 can protect from *maVie16* infections.

To test whether ACE2 could also be used therapeutically to protect from *maVie16*-induced lung pathologies in BALB/c and C57BL/6 mice, we performed therapeutic inhalation treatments with recombinant murine soluble (rms) ACE2. *MaVie16*-infected (1×10^5 TCID₅₀) BALB/c mice which were treated with rmsACE2 (Figure 7F and S7C), did not lose body weight (Figure 7G), developed less hypothermia (Figure 7H), exhibited lower lung weights (Figure 7I) and were largely protected from pneumonia (day 5 p.i.; Figure 7J), had lower lung viral loads (Figure 7K) and fewer blood neutrophils (Figure 7L) than vehicle-treated animals, indicating marked prevention of *mCOVID-19* development. Further, we found fewer SARS-CoV-2 nucleocapsid-positive cells in lungs of BALB/c animals treated with rmsACE2 5 days after infection with *maVie16* as compared to controls (Figure S7D). Similarly, rmsACE2 treatment of *maVie16*-infected (5×10^5 TCID₅₀) C57BL/6 mice (Figure S7E) prevented weight loss and reduced the viral load (Figure S7F and G, respectively) while it did not affect temperature, lung weight and blood leukocyte numbers (Figure

S7G, H and J, respectively). These data show that inhalation of rmsACE2 can markedly prevent *maVie16*-induced (m)COVID-19.

Discussion

With *maVie16*, we here generated a novel tool to study and experimentally dissect COVID-19 in vivo. Our passaging protocol led to an initial fast adaptation of the *BavPat1* to the new host, indicated by a rapid increase in virus genome copy number found in the lung. This increased mouse infectivity coincided with the appearance of a spike protein mutation at position 498, which was intentionally introduced using an engineering approach by the Baric group in an earlier attempt to increase mouse specificity of SARS-CoV-2 (Dinnon *et al.*, 2020). Interestingly, another *maVie16* spike protein mutation (at position 493) was also found in the mouse adapted variant of the engineered virus after 10 passages through BALB/c mice (Gu *et al.*, 2020; Huang *et al.*, 2021; Leist *et al.*, 2020) and reported to improve spike-mAce2 interaction (Adams *et al.*, 2021).

The K417T Spike protein mutation was also found in the Gamma/P1 SARS-CoV-2 VOC (Voloch *et al.*, 2020) and the same lysine was changed to an asparagine in the Beta/B.1.351 VOC (Tegally *et al.*, 2020). Both variants have been shown to replicate in laboratory mice (Montagutelli *et al.*, 2021) and in both K417T/N was exclusively observed in conjunction with the mutations N501Y and E484K. While N501Y is suspected to boost infectivity, E484K might contribute to antibody escape and immune evasion. In its interaction with hACE2, E484 is postulated to form a salt-bridge with K31 in hACE2, while the neighboring D30 interacts with K417. Mutating K417 and E484 leads to an intramolecular salt-bridge between D30 and K31 in hACE2, having only minor effects on receptor interaction (Cheng *et al.*, 2021). As outlined above, with aspartic acid replaced by asparagine at position 30 in mACE2, spike protein amino acid K417 no longer has a strong interaction partner and mutation to T417 in *maVie16* is favorable. These data indicate that K417T *per se* might not itself be involved in immune escape mechanisms, but rather emerged to stabilize the interaction with mACE2. Our *in silico* modeling provides strong evidence that these spike protein mutations in *maVie16* support the molecular interaction with mACE2, thereby facilitating infections and the development of severe COVID-19 in mice. At the same time, structural analysis did not support an altered binding of *maVie16* Spike to hACE2, which was confirmed by propagation experiments with *BavPat1* and *maVie16* in human Caco-2 cells.

While inducing profound disease and mortality in BALB/c mice, *maVie16* also induced substantial bodyweight loss and pneumonia in adult C57BL/6 mice. In addition, C57BL/6 mCOVID-19 recapitulated critical immunological aspects observed in human COVID-19, including peripheral leuko- and lymphopenia, pneumonia and antigen-specific adaptive immunity. In addition, mCOVID-19 is characterized by an early pDC mobilization in blood and lung, associated with a fast pulmonary type I IFN response. The susceptibility of C57BL/6 animals proves particularly valuable since a large number of genetically modified mice is available on this background. A side-by-side comparison of BALB/c versus C57BL/6 mice revealed increased lung expression of type II IFN and IFN-driven genes in the BALB/c background, supporting the notion that pronounced inflammation is linked to more severe pathology. A detrimental role for cytokines, specifically IFN γ and TNF, had been previously associated with severe COVID-19 and experimentally identified as risk factor for severe disease in SARS-CoV-2-infected *K18-hACE2* mice, by causing a form of inflammatory cell death termed *PANoptosis* (Karki *et al.*, 2021). We also tested this hypothesis, and found that administration of IFN γ - and TNF-blocking antibodies significantly reduced disease burden and inflammation in *maVie16*-infected BALB/c mice. The role of other cytokines and chemokines as well as innate antiviral immunity or defined cell populations can now be genetically and experimentally dissected using our *maVie16* infection model.

Several studies based on crystallography (Wrapp *et al.*, 2020; Yan *et al.*, 2020), modeling (Rodrigues *et al.*, 2020) or *in vitro* experiments (Cai *et al.*, 2021; Hoffmann *et al.*, 2020; Monteil *et al.*, 2020) propose ACE2 as the main entry receptor for SARS-CoV-2. The relevance of ACE2 is further supported by *in vivo* experiments using *K18-hACE2* mice (Oladunni *et al.*, 2020) or viral vector-mediated hACE2 delivery systems (Rathnasinghe *et al.*, 2020). Although these experiments have shown that ACE2 expression is sufficient for infection, definitive proof of an essential *in vivo* role of ACE2 in COVID-19 has not been provided so far. This is of particular importance because additional receptors have been proposed that could also permit SARS-CoV2 infections (Cantuti-Castelvetri *et al.*, 2020; Daly *et al.*, 2020; Wang *et al.*, 2020). Using *Ace2*-deficient mice, we here demonstrate the strict dependence of *maVie16* infectivity and pathogenicity on ACE2 expression *in vivo*. Furthermore, we exploited this mechanistic insight and treated animals with rmsACE2 inhalation and observed a substantial protection of BALB/c and C57BL/6 mice from developing mCOVID-19. A recently published genome-wide association study across more than 50 000 COVID-19 patients and more than 700 000 non-infected individuals revealed a rare variant that was associated with down-regulated ACE2 expression and reduced risk of COVID-19 (Horowitz *et al.*, 2021), providing additional evidence for the importance of ACE2

for SARS-CoV-2 infection in humans. The principal effectiveness of recombinant human soluble (rhs) ACE2 towards SARS-CoV-2 was demonstrated earlier in organoids, as it slowed viral replication in this setting (Monteil *et al.*, 2020). It has been recently proposed that soluble ACE2 might enhance SARS-CoV-2 infections (Yeung *et al.*, 2021), however our data do not support this. Moreover, using hamsters (Higuchi *et al.*, 2021; Linsky *et al.*, 2020) and the *K18 hACE2* mouse model (Hassler *et al.*, 2021), it has also been shown that different forms of ACE2 can protect from disease, providing – together with our novel *murine COVID-19* model – pre-clinical proof-of-concept that ACE2 can be used as a therapy. RhsACE2, prepared in the same way as rmsACE2 we used for our inhalation experiments (Monteil *et al.*, 2020), is now being tested in clinical trials in COVID-19 patients with first promising results (Zoufaly *et al.*, 2020). Considering the emergence of variants that can escape in part vaccine efficacy and approved antibody therapies (Yuan *et al.*, 2021; Zhou *et al.*, 2021) and the fact that these variants have been apparently selected for better ACE2 binding (Tian *et al.*, 2021; Yuan *et al.*, 2021), ACE2 inhalation has the potential to prevent or treat early stages of SARS-CoV-2 infections irrespective of the virus variant. However, whether inhalable ACE2 indeed constitutes a universal strategy against current and future SARS-CoV-2 variants needs careful testing in clinical trials.

Overall, we here report the development of a novel mouse-adapted SARS-CoV-2, which induces *mCOVID-19* in both BALB/c and C57BL/6 backgrounds. Our findings on the essential role of ACE2 in *in vivo* infections and of recombinant mACE2 administration and IFN γ /TNF blocking as therapeutic options provide a first glimpse of the potential of this new tool to increase our understanding of COVID-19 *in vivo* of to foster the discovery of novel therapeutic options.

Author contributions

R.G., P.S., L.P., and A.HI. performed all of the experiments involving SARS-CoV-2, including isolation, culture and animal experiments. K.L. and L.P. performed PCR experiments, A.HI. performed all histological staining. F.O. analyzed lung histology slides. A.R. generated TMPRSS2 overexpressing Vero cells, supported by H.S., G.W. produced and provided mrACE2. T.C., J.W.P. and C.O. performed the molecular modeling, and B.A., L.E. and A.B. sequenced and analyzed viral strains. L.B. provided critical reagents. S.J.F.C., A.Ha. and J.M.P. provided critical reagents and contributed to experimental design of ACE2-related studies. N.M. and A. M. provided critical input on experiments and supported infectious research. R.G., P.S. and S.K. conceived the project and together with L.P. and J.M.P. wrote the manuscript. All authors read and approved the manuscript.

Declaration of interests

J.M.P. declares a conflict of interest as a founder and shareholder of Apeiron Biologics. G.W. is an employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients.

Acknowledgements

We thank the animal care takers and veterinarians at the animal facility of the Medical University of Vienna for expert help. Dr. Reinhard Grabherr, University of Natural Resources and Life Sciences, Vienna, Austria, kindly provided us with recombinant spike protein. We thank Hans-Christian Theussl, Rubina Koglgruber and Domagoj Cikes at the Institute for Molecular Biotechnology, Vienna, Austria, for their support. We appreciate support by the flow cytometry core facility of the Medical University of Vienna and the Biomedical Sequencing Facility (BSF) jointly run by the Medical University of Vienna and CeMM.

S.K. is supported by the Austrian Science Fund FWF within the special research programs Immunothrombosis (F54-10) and Chromatin Landscapes (F61-04). R.G. received funding by the Austrian Science Fund FWF (ZK57-B28) and P.S. acknowledges funding by the Austrian Science Fund (FWF) (P31113-B30). A.O.R. and H.S. were supported by the FWF (P 34253-B). B.A. was supported by the Austrian Science Fund (FWF) DK W1212. J.M.P. and the research leading to these results has received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences, the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005026, and the Canada 150 Research Chairs Program F18-01336 as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015.

Figures & figure legends

Figure 1

Figure 1: Serial pulmonary passaging of SARS-CoV-2 through BALB/c mice leads to mouse adaptation and generation of the mouse-virulent virus *maVie16*

(A) Experimental strategy for generation of *maVie16*. BALB/c mice were intranasally inoculated with *BavPat1* (Passage 0/P0), followed by serial passaging of virus-containing cell-free lung homogenates of infected mice every 3 days. Passaging was repeated 15 times. (B) Lung tissue virus genome copy numbers (determined by real-time PCR) of mice 3 days after infection with virus of different passages as indicated. (C) Bodyweight (percentage of initial) of mice 3 days after infection. (D) Body temperature before and 3 days after infection. (E) Lung tissue expression fold change (compared to P0 mean; analyzed by real-time PCR) of indicated genes 3 days after infection. (B to E) n = 1-3; (B, C and E): symbols represent individual mice; Kruskal-Wallis test (vs. P0) with Dunn's multiple comparisons test; (D) mean +/-SD; 2way ANOVA with Sidak test (vs. the respective initial body temperature); * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$; numbers above bars show the actual P value.

A *maVie16* mutations

Allele Frequency

K417T K417R Q493R Q498H1 T3113I D3119A F3557L G5075G Y5548C V5550L S6fs S6-113del S16S L19F A85V D61L C27393T C27889T A211A

Figure 2: *maVie16* possesses a distinct pattern of mutations and mediates *in vivo* pathology via ACE2

(A) Overview of allele frequencies of mutated amino acids detected in *maVie16* by sequencing. Labels on top indicate the associated protein (SGP: Spike glycoprotein; ORF: open reading frame; MGP: membrane glycoprotein). (B) Spike protein mutation dynamics. (C) Modelling and location of spike mutations. Spike trimer in cyan blue and green, mACE2 in magenta cartoon representation. Glycans in stick representations. (D) Modelling of specific *BavPat1* (upper row) and *maVie16* (lower row) amino acid regions in green (respective mutated positions are highlighted in yellow and labelled in green) and their interaction with mouse ACE2 (in magenta; positions of interest are labelled in magenta or black).

Figure 3

Figure 3: Respiratory *maVie16* infection causes dose-dependent pathology in BALB/c and C57BL/6 mice

(A-C and G) BALB/c (B/c) or (D-F and H) C57BL/6 (B/6) mice were intranasally inoculated with different doses of *maVie16* as indicated and monitored for (A and D) bodyweight, (B and E) survival and (C and F) body temperature over 7 days; dashed lines in A and C indicate trajectories of groups lacking full group size due to death of animals (see B). (G and H) Lung sections (hematoxylin & eosin stain) from mice three days after infection with 10^5 TCID₅₀ *maVie16*; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars indicate 100 μ m. (I) Histological score for analysis of lung sections as described in (G) and (H); symbols represent individual mice; (A, C, D, F) mean $\pm$ SD; (B) Mantel-Cox test (vs. 4×10^3 TCID₅₀); ** $P \leq 0.01$; the number next to the symbol shows the actual P value;

Figure 4

A

B Blood pDCs (in live/CD45⁺)
Days post infection

C

D

Figure 4: *m*COVID-19 is associated with transient lymphopenia, pulmonary dendritic cell and T cell infiltration and pneumonia

C57BL/6 mice were intranasally infected with PBS (= group 0) or 5×10^5 TCID₅₀ *maVie16* and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Flow cytometry analysis of blood cell populations. (B) Density plot representation of blood plasmacytoid dendritic cells (pDCs; identified as live/CD45⁺/CD11c⁺/BST2⁺) analyzed by flow cytometry. (C) Flow cytometry analysis of whole lung cell populations (see Figure S3 for gating strategies). (D) Lung tissue expression fold change (compared to group 0 mean; analyzed by real-time PCR) of indicated genes from mice at the respective time points after infection. (A, C and D): symbols represent individual mice; Kruskal-Wallis test (vs. group 0) with Dunn's multiple comparisons test; * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$.

Figure 5

Figure 5: *mCOVID-19* induces transient pneumonia and antigen-specific adaptive immunity

C57BL/6 mice were intranasally infected with PBS (= group 0 or PBS) or 5×10^5 TCID₅₀ *maVie16* and sacrificed after 2, 5, 7 or 14 days for subsequent analysis. (A) Lung tissue virus genome copy numbers (determined by real-time PCR). (B) Lung tissue weight. (C) Representative lung immunohistochemistry (anti-SARS-CoV-2 nucleocapsid stain, counterstained with hematoxylin) pictures; black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 μ m. (D) Lung pathology score based on histological analysis of lung tissue sections. (E) Analysis (by ELISA) of SARS-CoV-2 spike-specific IgG1, IgG2b and IgA plasma antibody titers 14 days after infection. (A, B, D, E) mean +SD; symbols represent individual mice; (A, B, D): Kruskal-Wallis test (vs. (A) day 2 or (B and D) group 0) with Dunn's multiple comparisons test; (E) Mann-Whitney test; * $P \leq 0.05$; ** $P \leq 0.01$; *** $P \leq 0.001$;

Figure 6

A

B

C

D

E

F

G

Figure 6: BALB/c *mCOVID-19* is associated with an increased NK cell and interferon response and is ameliorated by IFN γ and TNF blockade

BALB/c (B/c) and C57BL/6 (B/6) mice were intranasally inoculated with 10^5 TCID $_{50}$ *maVie16* (+) or PBS (-). Samples for analyses were collected 3 days after infection. (A) Flow cytometry analysis of blood cell populations. (B) Flow cytometry analysis of whole lung NK cells and plasmacytoid dendritic cells (pDCs). Density plots represent examples of respective cell populations (NK cells pre-gated from live/CD45 $^+$ /Ly6G $^-$ /CD3 $^-$; pDCs pre-gated from live/CD45 $^+$) (C) Lung tissue expression fold change (compared to the respective mean of uninfected samples; analyzed by real-time PCR) of indicated genes. (D) Experimental scheme for E to G. BALB/c mice were infected with 10^5 TCID $_{50}$ *maVie16* and treated intraperitoneally on day 1 and 3 p.i. with a mix of 500 μ g anti-IFN γ and anti-TNF or with isotype control antibody. (E) Bodyweight and (F) temperature kinetics over 5 days after infection. (G) Lung weight on day 5 after infection. (A to C, G) mean $\pm$ SD; symbols represent individual mice; differences between infected groups were assessed using the Mann-Whitney test; (E and F) mean $\pm$ SD; 2way ANOVA with Dunnett's multiple comparisons test (vs. the respective initial bodyweight or temperature); in panels without respective labels, the groups were not significantly different ($P < 0.05$); * $P \leq 0.05$; ** $P \leq 0.01$;

Figure 7

Figure 7: *mCOVID-19* pathology depends on *Ace2* and is improved by recombinant ACE2 administration

(A) Experimental scheme for B to E: Male *Ace2*-deficient (*Ace2*^{-/-}) or control (*Ace2*^{+/-}) mice were infected with 5x 10⁵ TCID₅₀ *maVie16*. (B) Bodyweight and (C) temperature kinetics over 3 days after infection. (D) Lung tissue weight 3 days post infection (p.i.). (E) Lung histology 3 days after infection (left panels: hematoxylin & eosin stain; right panels: anti-SARS-CoV-2 nucleocapsid immune-stain); black rectangles in the upper pictures indicate the area magnified in the respective lower row picture; scale bars represent 100 µm. (F) Experimental scheme for G to L. BALB/c mice were infected with 10⁵ TCID₅₀ *maVie16* and treated daily intranasally up to day 4 p.i. with 100 µg recombinant murine soluble (rms) ACE2 or vehicle (the first treatment was administered together with virus). (G) Bodyweight and (H) temperature kinetics over 5 days after infection. (I) Lung weight, (J) lung histology (hematoxylin & eosin stain), (K) lung viral load, and (L) blood cells on day 5 after infection. (B, C, G, H) mean +/-SD; 2way ANOVA with Dunnett's multiple comparisons test (vs. the respective initial bodyweight or temperature); (D, I, K, L) Mann-Whitney test; * *P* ≤ 0.05; ** *P* ≤ 0.01; *** *P* ≤ 0.001; ns: not significant (*P* > 0.05)

References

Adams, L.E., Dinno, K.H., 3rd, Hou, Y.J., Sheahan, T.P., Heise, M.T., and Baric, R.S. (2021). Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. *mBio* 12. 10.1128/mBio.03149-20.

Bjorkstrom, N.K., Strunz, B., and Ljunggren, H.G. (2021). Natural killer cells in antiviral immunity. *Nat Rev Immunol.* 10.1038/s41577-021-00558-3.

Cai, Y., Zhang, J., Xiao, T., Lavine, C.L., Rawson, S., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A., et al. (2021). Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. *Science*. 10.1126/science.abi9745.

Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science* 370, 856-860. 10.1126/science.abd2985.

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 130, 2620-2629. 10.1172/JCI137244.

Cheng, M.H., Krieger, J.M., Kaynak, B., Arditi, M., and Bahar, I. (2021). Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment. *bioRxiv*, 2021.2001.2010.426143. 10.1101/2021.01.10.426143.

Daly, J.L., Simonetti, B., Klein, K., Chen, K.E., Williamson, M.K., Anton-Plagaro, C., Shoemark, D.K., Simon-Gracia, L., Bauer, M., Hollandi, R., et al. (2020). Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science* 370, 861-865. 10.1126/science.abd3072.

Damas, J., Hughes, G.M., Keough, K.C., Painter, C.A., Persky, N.S., Corbo, M., Hiller, M., Koepfli, K.P., Pfenning, A.R., Zhao, H., et al. (2020). Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. *Proc Natl Acad Sci U S A* 117, 22311-22322. 10.1073/pnas.2010146117.

Dinno, K.H., 3rd, Leist, S.R., Schafer, A., Edwards, C.E., Martinez, D.R., Montgomery, S.A., West, A., Yount, B.L., Jr., Hou, Y.J., Adams, L.E., et al. (2020). A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature* 586, 560-566. 10.1038/s41586-020-2708-8.

Grant, R.A., Morales-Nebreda, L., Markov, N.S., Swaminathan, S., Querrey, M., Guzman, E.R., Abbott, D.A., Donnelly, H.K., Donayre, A., Goldberg, I.A., et al. (2021). Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature* 590, 635-641. 10.1038/s41586-020-03148-w.

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020). Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* 369, 1603-1607. 10.1126/science.abc4730.

Hassler, L., Wysocki, J., Gelarden, I., Tomatsidou, A., Gula, H., Nicoleas, V., Randall, G., Henkin, J., Yeldandi, A., and Battle, D. (2021). A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection. *bioRxiv*, 2021.2003.2012.435191. 10.1101/2021.03.12.435191.

Higuchi, Y., Suzuki, T., Arimori, T., Ikemura, N., Mihara, E., Kirita, Y., Ohgitani, E., Mazda, O., Motooka, D., Nakamura, S., et al. (2021). Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. *Nat Commun* 12, 3802. 10.1038/s41467-021-24013-y.

Hikmet, F., Mear, L., Edvinsson, A., Micke, P., Uhlen, M., and Lindskog, C. (2020). The protein expression profile of ACE2 in human tissues. *Mol Syst Biol* 16, e9610. 10.15252/msb.20209610.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278. 10.1016/j.cell.2020.02.052.

Horowitz, J.E., Kosmicki, J.A., Damask, A., Sharma, D., Roberts, G.H.L., Justice, A.E., Banerjee, N., Coignet, M.V., Yadav, A., Leader, J.B., et al. (2021). Common genetic variants identify targets for COVID-19 and individuals at high risk of severe disease. *medRxiv*, 2020.2012.2014.20248176. 10.1101/2020.12.14.20248176.

Huang, K., Zhang, Y., Hui, X., Zhao, Y., Gong, W., Wang, T., Zhang, S., Yang, Y., Deng, F., Zhang, Q., et al. (2021). Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. *EBioMedicine* **67**, 103381. 10.1016/j.ebiom.2021.103381.

Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2021). Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. *Cell* **184**, 149-168 e117. 10.1016/j.cell.2020.11.025.

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* **11**, 875-879. 10.1038/nm1267.

Kumari, P., Rothan, H.A., Natekar, J.P., Stone, S., Pathak, H., Strate, P.G., Arora, K., Brinton, M.A., and Kumar, M. (2021). Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. *Viruses* **13**. 10.3390/v13010132.

Leist, S.R., Dinno, K.H., 3rd, Schafer, A., Tse, L.V., Okuda, K., Hou, Y.J., West, A., Edwards, C.E., Sanders, W., Fritch, E.J., et al. (2020). A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. *Cell* **183**, 1070-1085 e1012. 10.1016/j.cell.2020.09.050.

Linsky, T.W., Vergara, R., Codina, N., Nelson, J.W., Walker, M.J., Su, W., Barnes, C.O., Hsiang, T.Y., Esser-Nobis, K., Yu, K., et al. (2020). De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. *Science* **370**, 1208-1214. 10.1126/science.abe0075.

Liu, J., Li, Y., Liu, Q., Yao, Q., Wang, X., Zhang, H., Chen, R., Ren, L., Min, J., Deng, F., et al. (2021). SARS-CoV-2 cell tropism and multiorgan infection. *Cell Discov* **7**, 17. 10.1038/s41421-021-00249-2.

Mangalmurti, N., and Hunter, C.A. (2020). Cytokine Storms: Understanding COVID-19. *Immunity* **53**, 19-25. 10.1016/j.immuni.2020.06.017.

McCray, P.B., Jr., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H.P., Halabi, C., Sigmund, C.D., et al. (2007). Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. *J Virol* **81**, 813-821. 10.1128/JVI.02012-06.

Merad, M., Subramanian, A., and Wang, T.T. (2021). An aberrant inflammatory response in severe COVID-19. *Cell Host Microbe* **29**, 1043-1047. 10.1016/j.chom.2021.06.018.

Montagutelli, X., Prot, M., Levillayer, L., Salazar, E.B., Jouvion, G., Conquet, L., Donati, F., Albert, M., Gambaro, F., Behillil, S., et al. (2021). The B.1.351 and P.1 variants extend SARS-CoV-2 host range to mice. *bioRxiv*, 2021.2003.2018.436013. 10.1101/2021.03.18.436013.

Monteil, V., Kwon, H., Prado, P., Hagelkrays, A., Wimmer, R.A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado Del Pozo, C., Prosper, F., et al. (2020). Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell* **181**, 905-913 e907. 10.1016/j.cell.2020.04.004.

Murgolo, N., Therien, A.G., Howell, B., Klein, D., Koeplinger, K., Lieberman, L.A., Adam, G.C., Flynn, J., McKenna, P., Swaminathan, G., et al. (2021). SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. *PLoS Pathog* 17, e1009225. 10.1371/journal.ppat.1009225.

Oladunni, F.S., Park, J.G., Pino, P.A., Gonzalez, O., Akhter, A., Allue-Guardia, A., Olmo-Fontanez, A., Gautam, S., Garcia-Vilanova, A., Ye, C., et al. (2020). Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. *Nat Commun* 11, 6122. 10.1038/s41467-020-19891-7.

Paranjpe, I., Russak, A.J., De Freitas, J.K., Lala, A., Miotto, R., Vaid, A., Johnson, K.W., Danieleto, M., Golden, E., Meyer, D., et al. (2020). Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City. *BMJ Open* 10, e040736. 10.1136/bmjopen-2020-040736.

Parolin, C., Virtuoso, S., Giovanetti, M., Angeletti, S., Ciccozzi, M., and Borsetti, A. (2021). Animal Hosts and Experimental Models of SARS-CoV-2 Infection. *Chemotherapy* 66, 8-16. 10.1159/000515341.

Rathnasinghe, R., Strohmeier, S., Amanat, F., Gillespie, V.L., Krammer, F., Garcia-Sastre, A., Coughlan, L., Schotsaert, M., and Uccellini, M.B. (2020). Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. *Emerg Microbes Infect* 9, 2433-2445. 10.1080/22221751.2020.1838955.

Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K.W., the Northwell, C.-R.C., Barnaby, D.P., Becker, L.B., Chelico, J.D., et al. (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 323, 2052-2059. 10.1001/jama.2020.6775.

Rodrigues, J., Barrera-Vilarmau, S., J, M.C.T., Sorokina, M., Seckel, E., Kastritis, P.L., and Levitt, M. (2020). Insights on cross-species transmission of SARS-CoV-2 from structural modeling. *PLoS Comput Biol* 16, e1008449. 10.1371/journal.pcbi.1008449.

Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Janke, C., Guggemos, W., et al. (2020). Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med* 382, 970-971. 10.1056/NEJMc2001468.

Shu, Y., and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill* 22. 10.2807/1560-7917.ES.2017.22.13.30494.

Sungnak, W., Huang, N., Becavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-Lopez, C., Maatz, H., Reichart, D., Sampaziotis, F., et al. (2020). SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med* 26, 681-687. 10.1038/s41591-020-0868-6.

Swiecki, M., and Colonna, M. (2015). The multifaceted biology of plasmacytoid dendritic cells. *Nat Rev Immunol* 15, 471-485. 10.1038/nri3865.

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., Msomi, N., et al. (2020). Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.2012.2021.20248640. 10.1101/2020.12.21.20248640.

Tian, F., Tong, B., Sun, L., Shi, S., Zheng, B., Wang, Z., Dong, X., and Zheng, P. (2021). Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2. *bioRxiv*, 2021.2002.2014.431117. 10.1101/2021.02.14.431117.

Voloch, C.M., Silva F, R.d., de Almeida, L.G.P., Cardoso, C.C., Brustolini, O.J., Gerber, A.L., Guimarães, A.P.d.C., Mariani, D., Costa, R.M.d., Ferreira, O.C., et al. (2020). Genomic characterization of a novel

SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv, 2020.2012.2023.20248598. 10.1101/2020.12.23.20248598.

Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J.Q., Du, P., Wei, D., Zhang, Y., Sun, X.X., Gong, L., et al. (2020). CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther* 5, 283. 10.1038/s41392-020-00426-x.

WHO (2021a). Tracking SARS-CoV-2 variants. <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.

WHO (2021b). WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>.

Winkler, E.S., Bailey, A.L., Kafai, N.M., Nair, S., McCune, B.T., Yu, J., Fox, J.M., Chen, R.E., Earnest, J.T., Keeler, S.P., et al. (2020). SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nat Immunol* 21, 1327-1335. 10.1038/s41590-020-0778-2.

Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S., and McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 367, 1260-1263. 10.1126/science.abb2507.

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 367, 1444-1448. 10.1126/science.abb2762.

Yeung, M.L., Teng, J.L.L., Jia, L., Zhang, C., Huang, C., Cai, J.P., Zhou, R., Chan, K.H., Zhao, H., Zhu, L., et al. (2021). Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. *Cell* 184, 2212-2228 e2212. 10.1016/j.cell.2021.02.053.

Yuan, M., Huang, D., Lee, C.D., Wu, N.C., Jackson, A.M., Zhu, X., Liu, H., Peng, L., van Gils, M.J., Sanders, R.W., et al. (2021). Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. *Science*. 10.1126/science.abh1139.

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 184, 2348-2361 e2346. 10.1016/j.cell.2021.02.037.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 395, 1054-1062. 10.1016/S0140-6736(20)30566-3.

Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbanjo, I.M., Miao, V.N., Tzouanas, C.N., Cao, Y., Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* 181, 1016-1035 e1019. 10.1016/j.cell.2020.04.035.

Zoufaly, A., Poglitsch, M., Aberle, J.H., Hoepler, W., Seitz, T., Traugott, M., Grieb, A., Pawelka, E., Laferl, H., Wenisch, C., et al. (2020). Human recombinant soluble ACE2 in severe COVID-19. *Lancet Respir Med* 8, 1154-1158. 10.1016/S2213-2600(20)30418-5.